News Image

NASDAQ:HALO, a strong growth stock, setting up for a breakout.

By Mill Chart

Last update: Jan 31, 2024

Exploring Growth Potential: HALOZYME THERAPEUTICS INC (NASDAQ:HALO) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and HALOZYME THERAPEUTICS INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected HALOZYME THERAPEUTICS INC on our screen for growth with base formation, suggesting it merits a closer look.

Understanding NASDAQ:HALO's Growth Score

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:HALO has earned a 8 for growth:

  • The Earnings Per Share has grown by an nice 12.96% over the past year.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 42.34% on average per year.
  • The Revenue has grown by 34.42% in the past year. This is a very strong growth!
  • HALO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.83% yearly.
  • The Earnings Per Share is expected to grow by 25.42% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 18.74% on average per year.

Health Assessment of NASDAQ:HALO

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:HALO has achieved a 7 out of 10:

  • HALO has an Altman-Z score of 3.24. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.24, HALO is doing good in the industry, outperforming 72.68% of the companies in the same industry.
  • With an excellent Debt to FCF ratio value of 4.24, HALO belongs to the best of the industry, outperforming 94.94% of the companies in the same industry.
  • A Current Ratio of 7.63 indicates that HALO has no problem at all paying its short term obligations.
  • The Current ratio of HALO (7.63) is better than 68.13% of its industry peers.
  • A Quick Ratio of 6.51 indicates that HALO has no problem at all paying its short term obligations.
  • HALO has a Quick ratio of 6.51. This is in the better half of the industry: HALO outperforms 62.06% of its industry peers.

Understanding NASDAQ:HALO's Profitability

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:HALO was assigned a score of 8 for profitability:

  • The Return On Assets of HALO (13.41%) is better than 98.65% of its industry peers.
  • HALO's Return On Equity of 101.89% is amongst the best of the industry. HALO outperforms 100.00% of its industry peers.
  • HALO has a Return On Invested Capital of 14.39%. This is amongst the best in the industry. HALO outperforms 97.64% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HALO is significantly above the industry average of 13.65%.
  • The 3 year average ROIC (36.78%) for HALO is well above the current ROIC(14.39%). The reason for the recent decline needs to be investigated.
  • HALO's Profit Margin of 32.53% is amongst the best of the industry. HALO outperforms 98.48% of its industry peers.
  • HALO's Profit Margin has improved in the last couple of years.
  • HALO has a better Operating Margin (40.35%) than 98.99% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • HALO has a better Gross Margin (76.68%) than 85.50% of its industry peers.

Looking at the Setup

ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:HALO scores a 7 out of 10:

HALO has a bad technical rating, but it does show a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period.

More Strong Growth stocks can be found in our Strong Growth screener.

Check the latest full fundamental report of HALO for a complete fundamental analysis.

Our latest full technical report of HALO contains the most current technical analsysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/26/2024, 7:00:02 PM)

After market: 38.88 +0.31 (+0.8%)

38.57

+0.11 (+0.29%)

HALO News

News Imagea day ago - Halozyme Therapeutics, Inc.Mahesh Krishnan Elected to Halozyme's Board of Directors

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr....

News Image2 days ago - InvestorPlace3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition

Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.

News Image4 days ago - Halozyme Therapeutics, Inc.Halozyme to Report First Quarter 2024 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results...

News Image4 days ago - ChartmillNASDAQ:HALO is not too expensive for the growth it is showing.

NASDAQ:HALO stands out as a growth opportunity that won't break the bank.

News Image11 days ago - ChartmillInvestors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.

News Image14 days ago - Market News VideoNotable Two Hundred Day Moving Average Cross - HALO
News Imagea month ago - BusinessInsiderThe 3 Best Biotech Stocks to Buy in Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech is an industry full of opportunity. It’s also known as one of the...

News Imagea month ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in Q2 2024

Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.

News Imagea month ago - Market News VideoFirst Week of May 17th Options Trading For Halozyme Therapeutics (HALO)
News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

News Imagea month ago - InvestorPlace7 Biotech Stocks to Buy as Sector Rotation Ramps Up

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

News Image2 months ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...

HALO Links
Follow us for more